NCT03972657
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 26 versions: 26 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 24 → 27 locations
- Notable Eligibility criteria expanded, about 17 words
- Primary endpoints: details revised at 1 of 9 entries
- Study sites: 24 to 26
- Secondary endpoints: details revised at 1 of 12 entries
- Minor Study sites: 22 to 24v24
- Minor Study sites: 21 to 22v23
- Minor Study sites: 17 to 21v22
Show 20 earlier versionsHide 20 earlier versions
Notable Primary and study completion dates pushed to Nov 15, 2027v21 Show 4 more changesShow less
- Primary endpoints revised (9)
- Eligibility criteria expanded, about 1 word
- Secondary endpoints revised (12)
- Study title expanded, about 1 word
- Minor Study sites: 16 to 17v20
- Minor Study sites: 15 to 16v19
- Minor Study sites: 14 to 15v18
Notable Eligibility criteria shortened, about 4 wordsv17 Show 6 more changesShow less
- Enrollment target: 297 to 345
- Study sites: 13 to 14
- Interventions: Cemiplimab (Drug), REGN5678 (Drug), Sarilumab (Drug) to Cemiplimab (Drug), REGN5678 (Drug)
- Secondary endpoints: 11 to 12
- Study title expanded, about 12 words
- Study arms: 3 to 4
Notable Primary completion date: Feb 13, 2024 to Aug 1, 2025v16 Show 8 more changesShow less
- Eligibility criteria expanded, about 130 words
- Primary endpoints: 8 to 9
- Enrollment target: 216 to 297
- Study completion date: Feb 19, 2025 to Jul 3, 2026
- Interventions: 18F-DCFPyL (Other), Cemiplimab (Drug), REGN5678 (Drug), Sarilumab (Drug) to Cemiplimab (Drug), REGN5678 (Drug), Sarilumab (Drug)
- Secondary endpoints revised (11)
- Study arms: 2 to 3
- Study title expanded, about 5 words
- Minor Study sites: 12 to 13v15
- Minor Study sites: 11 to 12v14
- Minor Site details revised at 1 of 11 sitesv13
Notable Enrollment target: 129 to 216v12 Show 4 more changesShow less
- Primary completion date: Jun 28, 2023 to Feb 13, 2024
- Study completion date: Jul 16, 2024 to Feb 19, 2025
- Interventions: 18F-DCFPyL (Other), Cemiplimab (Drug), REGN5678 (Drug) to 18F-DCFPyL (Other), Cemiplimab (Drug), REGN5678 (Drug), Sarilumab (Drug)
- Primary endpoints revised (8)
- Minor Study sites: 10 to 11v11
- Minor Study sites: 9 to 10v10
- Minor Study sites: 8 to 9v9
- Minor Study sites: 7 to 8v8
- Minor Study sites: 6 to 7v7
- Minor Primary completion date: Jun 16, 2024 to Jun 28, 2023
- Study completion date: Jun 16, 2024 to Jul 16, 2024
- Secondary endpoints: 12 to 11
- Site details revised at 1 of 6 sites
- Notable Primary and study completion dates: Sep 2, 2025 to Jun 16, 2024
- Eligibility criteria shortened, about 20 words
- Enrollment target: 123 to 129
- Notable Primary and study completion dates: Oct 30, 2024 to Sep 2, 2025
- Eligibility criteria expanded, about 55 words
- Interventions: Cemiplimab (Drug), REGN5678 (Drug) to 18F-DCFPyL (Other), Cemiplimab (Drug), REGN5678 (Drug)
- Notable Start date: Jun 26, 2019 to Aug 12, 2019
- Study sites: 1 to 6
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Primary and study completion dates: Jul 10, 2024 to Oct 30, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Through study completion, up to 5 years
Incidence and severity of Adverse Event of Special Interests (AESIs)
Timeframe: Through study completion, up to 5 years
Incidence and severity of Serious Adverse Events (SAEs)
Timeframe: Through study completion, up to 5 years
Number of participants with Grade ≥3 laboratory abnormalities
Timeframe: Through study completion, up to 5 years
Incidence of Dose-Limiting Toxicities (DLTs)
Timeframe: First dose through day 42 of last participant in each dose level
Concentration of REGN5678 in serum over time
Timeframe: Through study completion, up to 5 years
Concentration of REGN5678 in combination with cemiplimab in serum over time
Timeframe: Through study completion, up to 5 years
Composite Response Rate (CRR) of 50% decline of Prostate Specific Antigen (PSA) and/or confirmed radiographic response of complete (CR) or partial response (PR)
Timeframe: Through study completion, up to 5 years
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Timeframe: Through study completion, up to 5 years
Secondary (12)
CRR of 50% decline of PSA and/or confirmed radiographic of CR or PR
ORR per RECIST 1.1 criteria
Incidence and severity of TEAEs
Incidence and severity of AESIs
Incidence and severity of SAEs
Show 7 moreShow less
Number of participants with grade ≥3 laboratory abnormalities
Concentration of REGN5678 in serum over time
Concentration of REGN5678 in combination with cemiplimab in serum over time
Percentage of participants with ≥50% decline of PSA
Percentage of participants with ≥90% decline of PSA
Presence or absence of antibodies against REGN5678
Presence or absence of antibodies against cemiplimab
Arms and interventions
mCRPC - dose escalation cohortExperimental
REGN5678 with or without cemiplimab
mCRPC - dose expansion cohortExperimental
REGN5678 with or without cemiplimab
ccRCC - dose escalation cohortExperimental
REGN5678 with or without cemiplimab
ccRCC - dose expansion cohortExperimental
REGN5678 with or without cemiplimab
Drugs: REGN5678, Cemiplimab
Sites
27 sites in 2 countries
United States 24, South Korea 3